TPMT or TPMTD or Thiopurine S-Methyltransferase or Thiopurine Methyltransferase refers to either a gene or the enzyme encoded by it.
Function[edit | edit source]
TPMT has a role in the function of the immune system.
Thiopurine methyltransferase deficiency[edit | edit source]
TPMT deficiency is a genetic condition that means that the enzymes that help process thiopurine drugs have reduced activity. If people with TPMT deficiency take thiopurine drugs, they are at inceased risk of bone marrow damage.
Thiopurine genetic testing[edit | edit source]
Drug responses[edit | edit source]
Thiopurines are relatively common drugs, but thiopurine methyltransferase deficiency studies have found that 1 in 300 people have no thiopurine methyltransferase enzyme activity, and 11% have reduced activity.
Thiopurines (drugs)[edit | edit source]
Thiopurine drugs suppress immune system, they include:
Thiopurine drugs are used to treat:
- Crohn's disease
- Rheumatoid arthritis
- certain other autoimmune diseases
- some cancers, for example blood or immune cell cancers (leukemias, and lymphomas)
- to help prevent the rejection of organ transplants after organ transplants
ME/CFS[edit | edit source]
Genetic studies of ME/CFS patients have not so far identified any TPMT genes as possibly associated with ME/CFS.
See also[edit | edit source]
Learn more[edit | edit source]
- TPMT gene - MedlinePlus
- Thiopurine S-methyltransferase deficiency - MedlinePlus
- Thiopurine S methyltranferase deficiency - Genetic and Rare Diseases Information Center
- TPMT Gene - Gene cards
References[edit | edit source]
- "TPMT Gene - Thiopurine S-Methyltransferase Protein Coding". Gene cards. Retrieved April 7, 2022.
- "Thiopurine S-methyltransferase deficiency". Medline Plus. Retrieved April 8, 2022.
- Royal College of Physicians; British Pharmacological Society (2022), Personalised prescribing: using pharmacogenomics to improve patient outcomes. Report of a working party., London: RCP and BPS
- Lennard, Lynne (April 2014). "Implementation of TPMT testing: TPMT testing". British Journal of Clinical Pharmacology. 77 (4): 704–714. doi:10.1111/bcp.12226. PMC 3971986. PMID 23962279.
- "TPMT gene". Medline Plus. Retrieved April 8, 2022.
- Dibble, Joshua J; McGrath, Simon J; Ponting, Chris P (August 3, 2020). "Genetic risk factors of ME/CFS: a critical review". Human Molecular Genetics. 29 (R1): R117–R124. doi:10.1093/hmg/ddaa169. ISSN 0964-6906. PMC 7530519. PMID 32744306.
- Carruthers, Bruce M.; Jain, Anil Kumar; De Meirleir, Kenny L.; Peterson, Daniel L.; Klimas, Nancy G.; Lerner, A. Martin; Bested, Alison C.; Flor-Henry, Pierre; Joshi, Pradip; Powles, A C Peter; Sherkey, Jeffrey A.; van de Sande, Marjorie I. (2003), "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols" (PDF), Journal of Chronic Fatigue Syndrome, 11 (2): 7-115, doi:10.1300/J092v11n01_02
- Carruthers, BM; van de Sande, MI; De Meirleir, KL; Klimas, NG; Broderick, G; Mitchell, T; Staines, D; Powles, ACP; Speight, N; Vallings, R; Bateman, L; Bell, DS; Carlo-Stella, N; Chia, J; Darragh, A; Gerken, A; Jo, D; Lewis, DP; Light, AR; Light, KC; Marshall-Gradisnik, S; McLaren-Howard, J; Mena, I; Miwa, K; Murovska, M; Stevens, SR (2012), Myalgic encephalomyelitis: Adult & Paediatric: International Consensus Primer for Medical Practitioners (PDF), ISBN 978-0-9739335-3-6
- NICE Guideline Development Group (October 29, 2021). "Myalgic Encephalomyelitis (or Encephalopathy)/Chronic Fatigue Syndrome:diagnosis and management. NICE guideline". National Institute for Health and Care Excellence.